1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends

Worldwide - Hepatitis C Drugs Market & Pipeline Drugs Analysis to 2019

  • October 2014
  • 113 pages
  • Igate Research
Report ID: 2669356


Table of Contents

Search Inside

Hepatitis C (hep C) is a viral disease caused by the Hepatitis C virus (HCV) and transmitted by blood, primarily in health care settings. It can progressively damage the liver, and, if left untreated, cause liver cirrhosis, liver cancer, and death. Hep C is the leading cause of liver cancer and liver transplants. In addition, the virus is associated with a variety of conditions beyond liver disease, including diabetes and depression. In July 2013, the World Health Organization (WHO) estimated that over 150 Million people are chronically infected worldwide. The annual number of deaths due to HCV is estimated at 350,000 globally, or nearly 1,000 per day. The HCV pandemic is concentrated in middle-income countries (MICs); while 15% of the 150 million people with chronic HCV live in High income countries (HICs), 73% live in middle-income countries (MICs) and 12% in low-income countries (LICs).

The hepatitis C market is rapidly evolving as new launches prompt a significant paradigm shift in the treatment of the disease. In 2011, a breakthrough in HCV therapy was witnessed with the first two direct acting anti-HCV drugs (Incivek and Victrelis) came to market and were followed by the market approval of two additional anti-HCV drugs (Sovaldi and Olysio) in 2013. These new drugs have significantly improved HCV cure rates. Hepatitis C virus drug market is expected to nearly quadruple of its current figure by 2014. The world market for HCV drugs represents an area of potential opportunities in developed as well as developing countries. Because of the technological advancements and effectiveness, many big market players are focusing on development of innovative drugs for HCV. Major companies are forming coalitions and agreements to develop effective treatment on Hepatitis C virus. The Hepatitis C (HCV) market is entering a new stage due to the emergence of treatment innovations. The HCV market is expected to have the best growth opportunities over the coming decade.

Scope of Report

This research report provides an extensive analysis of the Hepatitis C Drugs Market and Forecast (2009 - 2019)
The report covers historical analysis of Hepatitis C Approved Drugs from (2009 - 2013), along with forecast figures for (2014 - 2019)
The report covers forecasted value of Hepatitis C - Pipeline Drugs Sales from (2014 - 2019)
The report provides a detailed analysis of 9 Companies Hepatitis C Pipeline Drugs - Clinical Trials
The report gives an insight on the Hepatitis C Deals and Acquisitions (2004 - 2014)

iGATE RESEARCH report entitled Worldwide - Hepatitis C Drugs Market and Pipeline Drugs Analysis to 2019 provides an in-depth analysis of the drugs, pipeline drugs and the key players that will shape the future of Hepatitis C Drugs Market. This 113 page report enriched with 27 Figures and 1 Table studies the Hepatitis C Drug Market Landscape.

This Report is analyzed from four view points: Approved drugs sales, Pipeline drugs sales, Company Wise Clinical Trial Analysis and Deals and Acquisitions in Hepatitis C Landscape.

Hepatitis C - Approved Drugs sales and Forecast Analysis (To 2019)

1. Pegasys
2. Pegintron
3. Incivek
4. Victrelis
5. Copegus
6. Rebetol
7. Virazole
8. Intron A
9. Olysio
10. Sovaldi
11. Daklinza

Hepatitis C - Pipeline Drugs Sales and Forecast (To 2019)

1. HCV Franchise (Bristol-Myers Squibb)
2. HCV Franchise (AbbVie)
3. PEG-Interferon Lambda
4. Vaniprevir
5. MK-8742 + MK-5172 33
6. Mericitabine or RG7128
7. Sunvepra (Asunaprevir)
8. ABT-450/r + Ombitasvir (ABT-267) + Dasabuvir (ABT-333)

Company Wise - Hepatitis C Pipeline Drugs Clinical Trials

1. Roche
2. AbbVie
3. Gilead Sciences
4. Achillion
5. Merck
6. Tibotec / Janssen
7. Bristol-Myers Squibb (BMS)
8. Vertex
9. Genentech

Source of Information

iGATE RESEARCH employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by iGATE Research dedicated team of qualified professionals with deep industry experience and expertise.

Research Methodologies

Primary Research Methodologies: Questionnaires, Surveys, Interviews with Individuals, Small Groups, Telephonic Interview, etc.

Secondary Research Methodologies: Printable and Non-printable sources, Newspaper, Magazine and Journal Content, Government And NGO Statistics, white Papers, Information on the Web, Information from Agencies Such as Industry Bodies, Companies Annual Report, Government Agencies, Libraries And Local Councils and a large number of Paid Databases.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:


The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Global Biosimilars and Follow-On Biologics Market 2017-2027

  • $ 3247
  • Industry report
  • May 2017
  • by Visiongain

Report Details The global biosimilars and follow-on biologics market is expected to grow at a CAGR of 38.8% in the first half of the forecast period and CAGR of 11.3% in the second half of the forecast ...

PharmaPoint: Human Immunodeficiency Virus (HIV) - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • April 2017
  • by GlobalData

PharmaPoint: Human Immunodeficiency Virus (HIV) - Global Drug Forecast and Market Analysis to 2025 Summary Global HIV therapeutics market was worth approximately US$16.3 billion in 2015, and GlobalData ...

Ledipasvir / Sofosbuvir Sales, Price Analysis, & Sales Forecast - 2017

  • $ 1100
  • Industry report
  • April 2017
  • by Fore Pharma

Fore Pharma has released its new research, Ledipasvir / Sofosbuvir Sales, Price Analysis, & Sales Forecast – 2017. Find out the sales of Ledipasvir / Sofosbuvir worldwide and by countries in North America, ...


Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.